Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday.

Wegovy weight loss sustained for four years in trial, Novo Nordisk says

Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in people aged 12 years or older with haemophilia A with or without inhibitors.

Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial

The Danish medicines agency on Monday warned of a supply shortage for two separate doses of Novo Nordisk's hugely popular weight loss drug Wegovy due to increasing demand.

Denmark faces Wegovy shortage due to rising demand, medicines agency says

Bernie Sanders has urged Denmark to rein in its most valuable company, Novo Nordisk, and force it to slash prices on popular weight loss and diabetes treatments Ozempic and Wegovy, taking his fight to lower “outrageously high” drug prices in the United States to the company's doorstep as its profits soar amid ongoing struggles to meet booming appetite for the revolutionary drugs.

Bernie Sanders Urges Ozempic Maker Novo Nordisk To Be Fair Over ‘Outrageously Expensive' U.S. Drug Prices

Novo Nordisk (NYSE:NVO) could be in line for ‘dramatic earnings upgrades' as pace builds on the rollout of its weight loss drugs, analysts say. Wegovy sales could hit 76 billion Danish Krone (US$11 billion) this year, Morgan Stanley (NYSE:MS) said in a note, after starter doses increased six-fold up to early May.

Novo Nordisk weight loss rollout to prompt ‘dramatic upgrades' - analysts

Exelixis

Novo Nordisk and Exelixis are favorites of billionaire Jim Simons' hedge fund. Novo Nordisk has a deep lineup and pipeline and expertise in diabetes and obesity.

Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?

ACM Research

Docebo

Grab Holdings Ltd

Leidos Hld

One Stop Systems

Silicon Laboratories

In an ecosystem where individuality is celebrated and groupthink is criticized, it may seem imprudent to target popular stocks among retail investors. However, putting minds together can often yield lucrative discoveries and opportunities.

7 Stocks That Ordinary Investors Can't Get Enough Of Right Now

Wegovy is a weight-loss drug that's proving it can do more than help people lose weight. Regulators recently approved it as a treatment for reducing cardiovascular risk.

3 Million Reasons Novo Nordisk Still Looks Like a Phenomenal Buy

Metaphore Biotechnologies said on Thursday it would collaborate with Novo Nordisk to develop up to two therapies for obesity management.

Metaphore Biotechnologies to partner with Novo Nordisk on obesity therapies

Novo Nordisk (NYSE:NVO) could see consensus estimates boosted over the coming years as sales of its weight loss drugs pick up in the US, analysts say. Novo has 12 million patients on its GLP-1-based drugs, Citi analysts highlighted in a note, while the addressable population for the weight loss treatment approaches one billion.

Novo Nordisk eyeing upside on US weight loss drug rollout - analysts

Eli Lilly

Eli Lilly and Novo Nordisk are boosting supply of their weight loss drugs, while Apple Watch's heart monitoring tech was approved for use in clinical studies.

Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply

AbbVie

Cytokinetics

Pfizer

Roivant Sciences Ltd

Viking Therapeutics

Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.

Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare

Amgen

Altimmune

AstraZeneca

Structure Therapeutics Inc

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S' 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 860.02 per share and has been calculated as the three-day volume weighted average market price from 2 May 2024 to 6 May 2024 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.

Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme

The Bill & Melinda Gates Foundation is committing $100 million to a new joint partnership that will support innovation and research that address global health challenges.

Gates Foundation joins Novo Nordisk, Wellcome on $300M global health effort

The Bill & Melinda Gates Foundation, Wellcome Trust and Novo Nordisk Foundation joined forces on Monday to tackle some of the world's most pressing health problems, an endeavor that pulls together three of philanthropy's biggest players to tap developments in science and technology at a time when funding and attention for global health among governments is faltering.

Gates, Novo Nordisk And Wellcome Commit $300 Million To Climate Change, Infectious Diseases And Nutrition

The outlook for Pfizer's experimental obesity drug danuglipron is murky at best. Pfizer could pick up another obesity drug via an acquisition, but management says a near-term deal is unlikely.

Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?

Broadcom

Tencent Holdings Limited

There are no true “under-the-radar stocks” in the traditional sense regarding companies with a market capitalization large enough to be viable candidates for a $1 trillion valuation in just six years. However, there are many overlooked gems whose immense potential fails to garner the attention it deserves from investors.

3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030

Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.

Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide

Novo Nordisk (NYSE:NVO)'s latest results have impressed analysts at Citi, who see little to stop the pharma's value increasing even further as weight control drug Wegovy grows in the US. “While periodic supply constraints continue to impact the business, scaling supply remains management's number one priority.

Novo Nordisk continues to impress, says buyer Citi

Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.

Wegovy maker Novo Nordisk down 4%, heads for worst day since October

Catalent

The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent.

US FTC seeks more information on Novo Nordisk parent-Catalent deal

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVE™, to develop differentiated small molecule therapeutics, today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01) – an oral NLRP3 inhibitor licensed by Novo Nordisk in September 2022. “.

Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk

An EU study confirms there's no evidence linking Ozempic and Wegovy to an increase in suicidal thoughts. Side effects could be a key differentiator when it comes to which weight-loss and diabetes drugs succeed.

This Is a Huge Sigh of Relief for Novo Nordisk Investors

News for Novo Nordisk Stock (NVO)